There's also the question of CBD's legality – something that's a lot grayer than the black-and-white picture most companies paint. The U.S. Drug Enforcement Administration considers CBD, like all cannabinoids, a schedule 1 drug. That means it's just as illegal as heroin and ecstasy. Meanwhile, hemp – a variety of the cannabis plant regulated by the U.S. Department of Agriculture – is legal , so long as its THC content is negligibly low. But because the agriculture department doesn't test for CBD – only THC – in hemp, more companies are getting away with selling products they say contain CBD, says Sara Jane Ward, an assistant professor of pharmacology at the Temple University Lewis Katz School of Medicine who's been studying CBD in rodent models for more than 10 years. Needless to say, the legality of CBD is "very confusing and very gray," she says.
Cannabigerol is known as the stem cell cannabinoid for its role as a precursor to other cannabinoids found in hemp and marijuana. Previously overlooked as a significant cannabinoid, the role of CBG is becoming better understood, and companies like Medical Marijuana, Inc.’s AXIM® Biotechnologies are starting to research its potential. Because most CBG is transformed into other cannabinoids like CBD or THC by the cannabis plant, natural CBG levels are low in most processed cannabis plants.
THC-dominant edibles (like chocolates) can carry an even higher risk. “It can take one or two hours to feel an effect from ingestion as opposed to a few seconds from inhalation,” says Dr. Bonn-Miller. “This makes titration very difficult.” Add to that, an edible is made to taste good. So you can easily eat more than you should in the course of a few minutes—and end up feeling negative effects hours later.
Not much, as far as humans are concerned—at least not yet. The vast majority of studies have been on animals, as of yet, and there are few high-quality studies on humans. Even the oil’s effect on pain—something that CBD oil is popularly used for—isn’t proven. “The studies available are small or not well designed,” says Dr. Devinsky. “There’s a lot of religion out there, but not a lot of data.”